Cullinan Therapeutics (CGEM)
Cullinan Therapeutics on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances).
7.6M
Short interest
settlement 2026-10-15
8.2
Days to cover
+3.1 days vs prior
81.1%
Short share of volume
2026-11-02
18
Fails to deliver
settlement 2026-09-28
Thu 5 Nov
Next earnings
estimated date
-$780K
Insider flow, 90 days
0 buys, 2 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in CGEM is 7,640,003 shares, down 1,989,014 shares over the last month. Over the last 48 readings it ranged from 5,845,639 shares (15 August 2025) to 10,597,500 shares (30 June 2026). At the reported average volume of 931K shares a day that is 8.2 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/cgem" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 7,640,003 | +0.1% | 930,539 | 8.21 |
| 2026-09-30 | 7,634,127 | -20.7% | 1,505,393 | 5.07 |
| 2026-09-15 | 9,629,017 | -7.2% | 884,954 | 10.88 |
| 2026-08-31 | 10,371,763 | -2.0% | 669,836 | 15.48 |
| 2026-08-14 | 10,588,430 | +3.3% | 685,400 | 15.45 |
| 2026-07-31 | 10,254,541 | -0.3% | 534,845 | 19.17 |
| 2026-07-15 | 10,285,963 | -2.9% | 675,823 | 15.22 |
| 2026-06-30 | 10,597,500 | +29.5% | 1,600,967 | 6.62 |
| 2026-06-15 | 8,185,218 | +2.6% | 1,301,502 | 6.29 |
| 2026-05-29 | 7,973,648 | -8.1% | 1,130,798 | 7.05 |
| 2026-05-15 | 8,680,186 | -1.4% | 1,060,154 | 8.19 |
| 2026-04-30 | 8,799,071 | +8.4% | 576,135 | 15.27 |
| 2026-04-15 | 8,114,946 | -3.3% | 768,528 | 10.56 |
| 2026-03-31 | 8,394,357 | +0.4% | 900,228 | 9.32 |
| 2026-03-13 | 8,364,143 | +3.5% | 787,004 | 10.63 |
| 2026-02-27 | 8,080,892 | +0.8% | 901,746 | 8.96 |
| 2026-02-13 | 8,015,222 | +0.5% | 686,719 | 11.67 |
| 2026-01-30 | 7,976,684 | -5.3% | 664,740 | 12.00 |
| 2026-01-15 | 8,421,475 | +3.5% | 691,615 | 12.18 |
| 2025-12-31 | 8,136,316 | +19.3% | 1,052,554 | 7.73 |
| 2025-12-15 | 6,821,318 | -0.8% | 1,276,633 | 5.34 |
| 2025-11-28 | 6,876,864 | +3.0% | 1,682,379 | 4.09 |
| 2025-11-14 | 6,678,836 | +2.6% | 693,746 | 9.63 |
| 2025-10-31 | 6,509,523 | -1.8% | 1,084,182 | 6.00 |
| 2025-10-15 | 6,629,787 | +8.7% | 1,832,351 | 3.62 |
| 2025-09-30 | 6,099,492 | -1.3% | 665,799 | 9.16 |
| 2025-09-15 | 6,181,110 | -1.0% | 736,386 | 8.39 |
| 2025-08-29 | 6,244,014 | +6.8% | 363,732 | 17.17 |
| 2025-08-15 | 5,845,639 | -9.3% | 343,344 | 17.03 |
| 2025-07-31 | 6,445,305 | +9.5% | 325,817 | 19.78 |
| 2025-07-15 | 5,884,616 | -1.8% | 281,142 | 20.93 |
| 2025-06-30 | 5,990,144 | +0.5% | 438,820 | 13.65 |
| 2025-06-13 | 5,960,723 | -3.6% | 313,851 | 18.99 |
| 2025-05-30 | 6,181,783 | +3.3% | 350,582 | 17.63 |
| 2025-05-15 | 5,985,004 | -20.0% | 533,771 | 11.21 |
| 2025-04-30 | 7,479,137 | -6.4% | 424,826 | 17.61 |
| 2025-04-15 | 7,992,466 | -6.3% | 571,080 | 14.00 |
| 2025-03-31 | 8,527,373 | -1.7% | 396,697 | 21.50 |
| 2025-03-14 | 8,674,784 | +0.2% | 448,408 | 19.35 |
| 2025-02-28 | 8,655,955 | -1.3% | 432,794 | 20.00 |
| 2025-02-14 | 8,773,501 | +0.5% | 420,170 | 20.88 |
| 2025-01-31 | 8,732,969 | -10.7% | 421,645 | 20.71 |
| 2025-01-15 | 9,780,040 | -0.4% | 587,574 | 16.64 |
| 2024-12-31 | 9,816,622 | +1.7% | 621,496 | 15.80 |
| 2024-12-13 | 9,652,522 | +5.4% | 520,456 | 18.55 |
| 2024-11-29 | 9,157,765 | +5.2% | 541,204 | 16.92 |
| 2024-11-15 | 8,709,252 | -3.5% | 611,640 | 14.24 |
| 2024-10-31 | 9,021,016 | -0.4% | 371,044 | 24.31 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of CGEM volume is 81.1%, up 9.0 points over the last five sessions. Over the last 30 readings it ranged from 45.1% (2 October 2026) to 83.4% (23 October 2026). The latest reading sits at the top of that range. The latest reading is 10.8 points above the 30-session average of 70.3%, on 293K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 237K | 293K | 81.1% | 18,306 |
| 2026-10-30 | 84K | 117K | 72.0% | 175 |
| 2026-10-29 | 98K | 152K | 64.0% | 0 |
| 2026-10-28 | 130K | 182K | 71.5% | 0 |
| 2026-10-27 | 102K | 129K | 79.0% | 1 |
| 2026-10-26 | 78K | 108K | 72.1% | 0 |
| 2026-10-23 | 105K | 126K | 83.4% | 0 |
| 2026-10-22 | 115K | 149K | 77.1% | 0 |
| 2026-10-21 | 185K | 237K | 78.3% | 0 |
| 2026-10-20 | 194K | 241K | 80.3% | 11,683 |
| 2026-10-19 | 201K | 301K | 66.6% | 0 |
| 2026-10-16 | 392K | 502K | 78.1% | 0 |
| 2026-10-15 | 214K | 327K | 65.6% | 0 |
| 2026-10-14 | 146K | 240K | 60.6% | 0 |
| 2026-10-13 | 135K | 189K | 71.4% | 16 |
| 2026-10-12 | 65K | 94K | 69.6% | 0 |
| 2026-10-09 | 121K | 187K | 64.6% | 0 |
| 2026-10-08 | 165K | 250K | 65.9% | 5,381 |
| 2026-10-07 | 137K | 284K | 48.3% | 200 |
| 2026-10-06 | 640K | 862K | 74.3% | 0 |
| 2026-10-05 | 289K | 376K | 76.7% | 911 |
| 2026-10-02 | 215K | 477K | 45.1% | 0 |
| 2026-10-01 | 211K | 293K | 71.9% | 86 |
| 2026-09-30 | 193K | 276K | 69.8% | 13 |
| 2026-09-29 | 344K | 461K | 74.6% | 0 |
| 2026-09-28 | 337K | 446K | 75.8% | 1,102 |
| 2026-09-25 | 456K | 703K | 65.0% | 5,333 |
| 2026-09-24 | 862K | 1.2M | 70.9% | 60,660 |
| 2026-09-23 | 741K | 1.0M | 71.3% | 16,417 |
| 2026-09-22 | 170K | 266K | 64.1% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 28 September 2026, the fails-to-deliver balance in CGEM is 18 shares, down 1,216 shares over the last settlement date. Over the last 30 readings it ranged from 11 shares (25 March 2026) to 102,547 shares (1 July 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-28 | 18 | $14.81 | $267 |
| 2026-09-11 | 1,234 | $21.00 | $26K |
| 2026-09-08 | 2,260 | $22.09 | $50K |
| 2026-08-27 | 18,411 | $22.85 | $421K |
| 2026-08-25 | 512 | $21.82 | $11K |
| 2026-08-17 | 828 | $20.34 | $17K |
| 2026-08-06 | 2,545 | $17.61 | $45K |
| 2026-07-23 | 667 | $17.65 | $12K |
| 2026-07-22 | 238 | $18.06 | $4K |
| 2026-07-20 | 30,695 | $17.69 | $543K |
| 2026-07-17 | 100 | $16.41 | $2K |
| 2026-07-09 | 1,158 | $18.43 | $21K |
| 2026-07-06 | 200 | $17.63 | $4K |
| 2026-07-01 | 102,547 | $18.21 | $1.9M |
| 2026-06-18 | 22,191 | $14.44 | $320K |
| 2026-06-11 | 543 | $12.05 | $7K |
| 2026-05-13 | 2,841 | $16.15 | $46K |
| 2026-04-23 | 417 | $13.84 | $6K |
| 2026-04-14 | 1,005 | $14.25 | $14K |
| 2026-03-25 | 11 | $13.64 | $150 |
| 2026-02-26 | 40,000 | $14.36 | $574K |
| 2026-02-24 | 104 | $13.99 | $1K |
| 2026-02-23 | 215 | $13.65 | $3K |
| 2026-02-20 | 58 | $13.88 | $805 |
| 2026-02-19 | 33,050 | $12.44 | $411K |
| 2026-02-18 | 666 | $12.19 | $8K |
| 2026-02-17 | 189 | $11.59 | $2K |
| 2026-02-02 | 90 | $11.96 | $1K |
| 2026-01-30 | 13 | $11.92 | $155 |
| 2026-01-08 | 6,419 | $10.94 | $70K |
Insider trades
SEC Form 4, newest first. JSONInsiders at CGEM reported 2 open-market sells worth $780K in the last 90 days and no open-market buys. Latest filing: Michaelson Jennifer (Chief Scientific Officer) on 2026-09-08.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-08 | Michaelson Jennifer | Chief Scientific Officer | Sell | 8K | $21.57 | $173K | 159K |
| 2026-09-08 | Michaelson Jennifer | Chief Scientific Officer | Exercise or conversion | 4K | $4.30 | $17K | 167K |
| 2026-08-13 | Michaelson Jennifer | Chief Scientific Officer | Sell | 30K | $20.26 | $608K | 163K |
| 2026-08-13 | Michaelson Jennifer | Chief Scientific Officer | Exercise or conversion | 30K | $4.30 | $129K | 193K |
| 2026-07-06 | Michaelson Jennifer | Chief Scientific Officer | Sell | 8K | $17.82 | $143K | 163K |
| 2026-07-06 | Michaelson Jennifer | Chief Scientific Officer | Exercise or conversion | 4K | $4.30 | $17K | 171K |
| 2026-06-30 | SUMER JACQUELYN L | Chief Legal Officer | Grant | 2K | $8.60 | $21K | 131K |
| 2026-06-30 | Fenton Mary Kay | Chief Financial Officer | Grant | 2K | $8.60 | $13K | 128K |
| 2026-05-05 | Michaelson Jennifer | Chief Scientific Officer | Sell | 200 | $15.58 | $3K | 167K |
| 2026-05-05 | Michaelson Jennifer | Chief Scientific Officer | Sell | 8K | $14.60 | $114K | 167K |
| 2026-05-05 | Michaelson Jennifer | Chief Scientific Officer | Exercise or conversion | 4K | $4.30 | $17K | 175K |
| 2026-03-05 | Michaelson Jennifer | Chief Scientific Officer | Sell | 8K | $15.68 | $125K | 171K |
| 2026-03-05 | Michaelson Jennifer | Chief Scientific Officer | Exercise or conversion | 4K | $4.30 | $17K | 179K |
| 2026-02-25 | Michaelson Jennifer | Chief Scientific Officer | Sell | 2K | $14.14 | $25K | 175K |
| 2026-02-24 | Michaelson Jennifer | Chief Scientific Officer | Sell | 4K | $14.47 | $52K | 177K |
| 2026-02-24 | Jones Jeffrey Alan | Chief Medical Officer | Sell | 5K | $14.47 | $66K | 160K |
| 2026-02-24 | SUMER JACQUELYN L | Chief Legal Officer | Sell | 4K | $14.47 | $52K | 128K |
| 2026-02-24 | AHMED NADIM | President and CEO | Sell | 14K | $14.47 | $196K | 391K |
| 2026-02-23 | Michaelson Jennifer | Chief Scientific Officer | Sell | 2K | $13.99 | $25K | 180K |
| 2026-02-20 | Fenton Mary Kay | Chief Financial Officer | Sell | 4K | $13.62 | $60K | 126K |
| 2026-02-20 | Jones Jeffrey Alan | Chief Medical Officer | Sell | 5K | $13.62 | $68K | 165K |
| 2026-02-20 | Michaelson Jennifer | Chief Scientific Officer | Sell | 8K | $14.30 | $114K | 182K |
| 2026-02-20 | Michaelson Jennifer | Chief Scientific Officer | Exercise or conversion | 8K | $4.30 | $34K | 190K |
| 2026-02-20 | Michaelson Jennifer | Chief Scientific Officer | Sell | 4K | $13.62 | $51K | 182K |
| 2026-02-20 | SUMER JACQUELYN L | Chief Legal Officer | Sell | 4K | $13.62 | $51K | 132K |
| 2026-02-20 | AHMED NADIM | President and CEO | Sell | 16K | $13.62 | $223K | 404K |
| 2026-02-18 | Fenton Mary Kay | Chief Financial Officer | Grant | 69K | $0.00 | $0 | 131K |
| 2026-02-18 | Michaelson Jennifer | Chief Scientific Officer | Grant | 58K | $0.00 | $0 | 186K |
| 2026-02-12 | Michaelson Jennifer | Chief Scientific Officer | Sell | 416 | $12.03 | $5K | 128K |
| 2026-01-22 | Michaelson Jennifer | Chief Scientific Officer | Sell | 4K | $12.30 | $49K | 129K |
| 2025-12-31 | Fenton Mary Kay | Chief Financial Officer | Grant | 27 | $6.49 | $175 | 62K |
| 2025-12-23 | AHMED NADIM | President and CEO | Sell | 10K | $10.01 | $99K | 421K |
| 2025-12-19 | Michaelson Jennifer | Chief Scientific Officer | Sell | 1K | $10.01 | $13K | 133K |
| 2025-12-18 | SUMER JACQUELYN L | Chief Legal Officer | Sell | 3K | $9.67 | $34K | 135K |
| 2025-12-18 | Jones Jeffrey Alan | Chief Medical Officer | Sell | 5K | $9.67 | $45K | 170K |
| 2025-12-18 | Michaelson Jennifer | Chief Scientific Officer | Sell | 3K | $9.67 | $28K | 134K |
| 2025-12-15 | Michaelson Jennifer | Chief Scientific Officer | Sell | 995 | $11.90 | $12K | 137K |
| 2025-12-12 | Michaelson Jennifer | Chief Scientific Officer | Sell | 2K | $12.38 | $27K | 138K |
| 2025-11-24 | Michaelson Jennifer | Chief Scientific Officer | Sell | 4K | $12.30 | $49K | 138K |
| 2025-10-28 | Nichols Weston | TenPercentOwner | Buy | 166K | $8.40 | $1.4M | 9.0M |
| 2025-10-28 | Lynx1 Capital Management LP | 10% owner | Buy | 166K | $8.40 | $1.4M | 9.0M |
| 2025-10-17 | Lynx1 Capital Management LP | 10% owner | Buy | 32K | $7.84 | $253K | 8.8M |
| 2025-10-16 | Lynx1 Capital Management LP | 10% owner | Buy | 150K | $8.86 | $1.3M | 8.8M |
| 2025-10-15 | Lynx1 Capital Management LP | 10% owner | Buy | 52K | $7.94 | $409K | 8.6M |
| 2025-10-14 | Lynx1 Capital Management LP | 10% owner | Buy | 15K | $7.59 | $114K | 8.6M |
| 2025-10-10 | Lynx1 Capital Management LP | 10% owner | Buy | 277K | $7.36 | $2.0M | 8.5M |
| 2025-10-09 | Lynx1 Capital Management LP | 10% owner | Buy | 626K | $6.70 | $4.2M | 8.3M |
| 2025-10-08 | Lynx1 Capital Management LP | 10% owner | Buy | 556K | $6.46 | $3.6M | 7.6M |
| 2025-02-25 | SUMER JACQUELYN L | Chief Legal Officer | Sell | 4K | $8.53 | $32K | 137K |
| 2025-02-25 | AHMED NADIM | President and CEO | Sell | 13K | $8.53 | $107K | 431K |
| 2025-02-25 | Michaelson Jennifer | Chief Scientific Officer | Sell | 4K | $8.53 | $32K | 142K |
| 2025-02-25 | Jones Jeffrey Alan | Chief Medical Officer | Sell | 5K | $8.53 | $42K | 174K |
| 2025-02-19 | Fenton Mary Kay | Chief Financial Officer | Grant | 60K | $0.00 | $0 | 60K |
| 2025-02-19 | Jones Jeffrey Alan | Chief Medical Officer | Grant | 65K | $0.00 | $0 | 179K |
| 2025-02-19 | AHMED NADIM | President and CEO | Grant | 180K | $0.00 | $0 | 443K |
| 2025-02-19 | SUMER JACQUELYN L | Chief Legal Officer | Grant | 50K | $0.00 | $0 | 141K |
| 2025-02-19 | Savill Corrine | Chief Business Officer | Grant | 38K | $0.00 | $0 | 241K |
| 2025-02-19 | Michaelson Jennifer | Chief Scientific Officer | Grant | 50K | $0.00 | $0 | 146K |
| 2025-01-06 | Michaelson Jennifer | Chief Scientific Officer | Sell | 4K | $12.51 | $50K | 96K |
| 2024-12-24 | AHMED NADIM | President and CEO | Sell | 8K | $11.87 | $100K | 263K |
| 2024-12-18 | Jones Jeffrey Alan | Chief Medical Officer | Sell | 5K | $11.41 | $53K | 114K |
| 2024-12-18 | SUMER JACQUELYN L | Chief Legal Officer | Sell | 3K | $11.41 | $40K | 91K |
| 2024-12-18 | Michaelson Jennifer | Chief Scientific Officer | Sell | 5K | $11.41 | $54K | 100K |
| 2024-12-12 | Michaelson Jennifer | Chief Scientific Officer | Sell | 3K | $12.52 | $44K | 104K |
| 2024-11-05 | Michaelson Jennifer | Chief Scientific Officer | Sell | 8K | $15.64 | $125K | 108K |
| 2024-09-05 | Michaelson Jennifer | Chief Scientific Officer | Sell | 8K | $18.09 | $145K | 116K |
| 2024-07-05 | Michaelson Jennifer | Chief Scientific Officer | Sell | 8K | $16.33 | $131K | 124K |
| 2024-07-01 | Michaelson Jennifer | Chief Scientific Officer | Grant | 2K | $9.00 | $21K | 132K |
| 2024-06-10 | Ebeling Thomas | Director | Exercise or conversion | 18K | $13.00 | $240K | 187K |
| 2024-05-23 | Ebeling Thomas | Director | Grant | 16K | $12.73 | $210K | 168K |
| 2024-05-23 | Ebeling Thomas | Director | Grant | 84K | $4.30 | $362K | 152K |
| 2024-05-07 | Michaelson Jennifer | Chief Scientific Officer | Sell | 6K | $30.06 | $169K | 130K |
| 2024-05-07 | Michaelson Jennifer | Chief Scientific Officer | Exercise or conversion | 6K | $4.30 | $24K | 135K |
| 2024-05-06 | Michaelson Jennifer | Chief Scientific Officer | Exercise or conversion | 50K | $4.30 | $215K | 188K |
| 2024-05-06 | Michaelson Jennifer | Chief Scientific Officer | Sell | 20K | $28.54 | $579K | 130K |
| 2024-05-06 | Michaelson Jennifer | Chief Scientific Officer | Sell | 38K | $27.82 | $1.0M | 150K |
| 2024-02-22 | SUMER JACQUELYN L | Chief Legal Officer | Grant | 50K | $0.00 | $0 | 94K |
| 2024-02-22 | Michaelson Jennifer | Chief Scientific Officer | Grant | 50K | $0.00 | $0 | 138K |
| 2024-02-22 | Jones Jeffrey Alan | Chief Medical Officer | Grant | 63K | $0.00 | $0 | 119K |
| 2024-02-22 | Trigilio Jeffrey | Chief Financial Officer | Grant | 50K | $0.00 | $0 | 134K |
| 2024-02-22 | Savill Corrine | Chief Business Officer | Grant | 38K | $0.00 | $0 | 203K |
| 2024-02-22 | AHMED NADIM | President and CEO | Grant | 160K | $0.00 | $0 | 272K |
| 2024-02-01 | Savill Corrine | Chief Business Officer | Exercise or conversion | 40K | $4.30 | $172K | 206K |
| 2024-02-01 | Savill Corrine | Chief Business Officer | Sell | 40K | $16.18 | $647K | 166K |
| 2024-01-29 | Savill Corrine | Chief Business Officer | Sell | 40K | $14.09 | $564K | 166K |
| 2024-01-29 | Savill Corrine | Chief Business Officer | Exercise or conversion | 40K | $4.30 | $172K | 206K |
| 2024-01-23 | Savill Corrine | Chief Business Officer | Sell | 21K | $12.46 | $266K | 166K |
| 2024-01-23 | Savill Corrine | Chief Business Officer | Exercise or conversion | 21K | $4.30 | $92K | 187K |
| 2024-01-22 | Savill Corrine | Chief Business Officer | Sell | 4K | $12.02 | $50K | 166K |
| 2024-01-22 | Savill Corrine | Chief Business Officer | Sell | 15K | $12.18 | $177K | 170K |
| 2024-01-22 | Savill Corrine | Chief Business Officer | Exercise or conversion | 15K | $4.30 | $63K | 185K |
| 2023-12-26 | AHMED NADIM | President and CEO | Sell | 4K | $9.24 | $39K | 112K |
| 2023-12-21 | Michaelson Jennifer | Chief Scientific Officer | Sell | 1K | $8.50 | $10K | 88K |
| 2023-12-21 | Trigilio Jeffrey | Chief Financial Officer | Sell | 2K | $8.50 | $16K | 84K |
| 2023-12-21 | SUMER JACQUELYN L | Chief Legal Officer | Sell | 1K | $8.50 | $12K | 44K |
| 2023-12-21 | Jones Jeffrey Alan | Chief Medical Officer | Sell | 2K | $8.50 | $16K | 56K |
| 2023-12-18 | Trigilio Jeffrey | Chief Financial Officer | Sell | 398 | $8.22 | $3K | 86K |
| 2023-12-18 | SUMER JACQUELYN L | Chief Legal Officer | Sell | 290 | $8.22 | $2K | 46K |
| 2023-12-18 | Jones Jeffrey Alan | Chief Medical Officer | Sell | 386 | $8.22 | $3K | 58K |
| 2023-12-18 | Michaelson Jennifer | Chief Scientific Officer | Sell | 238 | $8.22 | $2K | 89K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON12 Form 144 notices on file for CGEM worth $1.4M at the prices reported; 2 in the last 90 days worth $765K. Latest: JENNIFER MICHAELSON filed on 2026-09-08 to sell 8,000 shares ($177K) from 2026-09-08.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-09-08 | JENNIFER MICHAELSONOfficer | 8K | $177K | 0.012% | 2026-09-08 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-13 | JENNIFER MICHAELSONOfficer | 30K | $588K | 0.047% | 2026-08-13 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-06 | JENNIFER MICHAELSONOfficer | 8K | $141K | 0.013% | 2026-07-06 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-05 | JENNIFER MICHAELSONOfficer | 8K | $123K | 0.013% | 2026-05-05 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-05 | JENNIFER MICHAELSONOfficer | 8K | $130K | 0.014% | 2026-03-05 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-25 | JENNIFER MICHAELSONOfficer | 2K | $25K | 0.003% | 2026-02-25 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-23 | JENNIFER MICHAELSONOfficer | 2K | $24K | 0.003% | 2026-02-23 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-20 | JENNIFER MICHAELSONOfficer | 8K | $111K | 0.014% | 2026-02-20 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-22 | JENNIFER MICHAELSONOfficer | 4K | $46K | 0.007% | 2026-01-22 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-19 | JENNIFER MICHAELSONOfficer | 1K | $13K | 0.002% | 2025-12-19 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-15 | JENNIFER MICHAELSONOfficer | 995 | $12K | 0.002% | 2025-12-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-24 | JENNIFER MICHAELSONOfficer | 4K | $38K | 0.007% | 2025-11-24 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON13 holders report 5% or more of CGEM in their latest filing, all on Schedule 13G (passive). The largest reported stake is LAMPERT MARK N at 10.0% of the class (6,491,123 shares), filed 2026-08-14 for an event on 2026-06-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-14 | 13G/Ano. 8 | LAMPERT MARK Nindividual | 6.5M | 10.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 8 | BVF INC/ILcorporation | 6.5M | 10.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 8 | BVF PARTNERS L P/ILinvestment adviser, partnership | 6.5M | 10.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 8 | BVF GP HOLDINGS LLCother entity | 6.0M | 9.2% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 8 | BVF I GP LLCother entity | 3.7M | 5.7% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 8 | BIOTECHNOLOGY VALUE FUND L Ppartnership | 3.7M | 5.7% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 8 | BVF II GP LLCother entity | 2.3M | 3.5% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 8 | BIOTECHNOLOGY VALUE FUND II LPpartnership | 2.3M | 3.5% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 8 | Biotechnology Value Trading Fund OS LPpartnership | 401K | 0.6% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 8 | BVF Partners OS Ltd.corporation | 401K | 0.6% | 2026-06-30 |
| 2026-08-14 | 13G | T. Rowe Price Associates, Inc.investment adviser | 3.8M | 6.2% | 2026-06-30 |
| 2026-08-07 | 13G | STATE STREET CORPORATIONparent holding company | 3.7M | 6.0% | 2026-06-30 |
| 2026-03-26 | 13G/Ano. 1 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-03-04 | 13G | Kynam Capital Management, LPinvestment adviser | 3.1M | 5.3% | 2025-12-31 |
| 2026-03-04 | 13G | Kynam Capital Management GP, LLCother entity | 3.1M | 5.3% | 2025-12-31 |
| 2026-03-04 | 13G | Yue Tangindividual | 3.1M | 5.3% | 2025-12-31 |
| 2025-11-14 | 13G/Ano. 1 | Kenneth Griffinparent holding company, individual | 2.0M | 3.4% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | Citadel GP LLCparent holding company, other entity | 1.8M | 3.1% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | Citadel Advisors LLCinvestment adviser, parent holding company, other entity | 1.8M | 3.1% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | Citadel Advisors Holdings LPparent holding company, partnership | 1.8M | 3.1% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | Citadel Securities LLCbroker-dealer, other entity | 148K | 0.3% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | Citadel Securities Group LPparent holding company, partnership | 148K | 0.3% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | Citadel Securities GP LLCparent holding company, other entity | 148K | 0.3% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | LYNX1 CAPITAL MANAGEMENT LPpartnership | 5.8M | 9.8% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | WESTON NICHOLSindividual | 5.8M | 9.8% | 2025-09-30 |
| 2025-11-13 | 13G/Ano. 1 | Deerfield Mgmt, L.P.partnership | 2.9M | 5.0% | 2025-09-30 |
| 2025-11-13 | 13G/Ano. 1 | Deerfield Management Company, L.P.partnership | 2.9M | 5.0% | 2025-09-30 |
| 2025-11-13 | 13G/Ano. 1 | Deerfield Partners, L.P.partnership | 2.9M | 5.0% | 2025-09-30 |
| 2025-11-13 | 13G/Ano. 1 | James E. Flynnindividual | 2.9M | 5.0% | 2025-09-30 |
13F holders
Tracked managers holding CGEM at their latest 13F. JSON7 of the 30 tracked managers held CGEM at their latest 13F, $37.1M in total at quarter-end prices. AQR Capital Management is the largest at $10.6M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 4 added shares and 3 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| AQR Capital Management | 2026-06-30 | 581K | $10.6M | 0.00% | +220K |
| Citadel Advisors | 2026-06-30 | 397K | $7.2M | 0.00% | +145K |
| Millennium Management | 2026-06-30 | 346K | $6.3M | 0.00% | -350 |
| Renaissance Technologies | 2026-06-30 | 327K | $6.0M | 0.01% | +3K |
| Two Sigma Investments | 2026-06-30 | 273K | $5.0M | 0.00% | -249K |
| Point72 Asset Management | 2026-06-30 | 75K | $1.4M | 0.00% | -830K |
| Fisher Asset Management | 2026-06-30 | 36K | $656K | 0.00% | new |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Cullinan Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Cullinan Therapeutics (CGEM), SEC CIK 1789972, listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances). The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-28.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-09-08.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-14.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-06.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-08.JSON and CSV
- Company record
- EDGAR filing index for CIK 1789972Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as biological products, (no diagnostic substances)
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of CGEM is sold short?
7,640,003 shares were held short at the 2026-10-15 settlement, 8.2 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is CGEM's daily short volume?
On 2026-11-02, 237,436 of the 292,728 CGEM shares reported to FINRA were sold short, 81.1% of the day's reported volume. Short volume is a flow for one day, not a position.
Does CGEM have fails to deliver?
The SEC's latest file shows 18 CGEM shares failed to deliver at settlement 2026-09-28. Fails are reported per settlement date and published twice a month with a lag.
Are CGEM insiders buying or selling?
Insiders at CGEM reported 2 open-market sells worth $780K in the last 90 days and no open-market buys. Latest filing: Michaelson Jennifer (Chief Scientific Officer) on 2026-09-08.
Have CGEM insiders filed to sell?
12 Form 144 notices on file for CGEM worth $1.4M at the prices reported; 2 in the last 90 days worth $765K. Latest: JENNIFER MICHAELSON filed on 2026-09-08 to sell 8,000 shares ($177K) from 2026-09-08.
Who owns 5% or more of CGEM?
13 holders report 5% or more of CGEM in their latest filing, all on Schedule 13G (passive). The largest reported stake is LAMPERT MARK N at 10.0% of the class (6,491,123 shares), filed 2026-08-14 for an event on 2026-06-30.
Which tracked 13F managers own CGEM?
7 of the 30 tracked 13F managers held CGEM shares at their latest filing, $37.1M in all. The largest: Cliff Asness's AQR Capital Management (581K shares, $10.6M), Ken Griffin's Citadel Advisors (397K shares, $7.2M), Izzy Englander's Millennium Management (346K shares, $6.3M), Renaissance Technologies (327K shares, $6.0M), Two Sigma Investments (273K shares, $5.0M), Steve Cohen's Point72 Asset Management (75K shares, $1.4M). The table above lists all 7.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.